Enorama Pharma AB OMXSTO:ERMA:
SUBSIDIARY INTENDS TO APPEAL FDA'S RTF DECISION
COMPANY IN CONTACT WITH FDA FOR CLARITY ON REGULATORY STATUS
ANALYZING FDA DECISION AND EVALUATING CONSEQUENCES
Enorama Pharma Subsidiary Intends To Appeal FDA's Refuse-To-File Decision
Earlier from Enorama Pharma
- Bulletin from the extraordinary general meeting in Enorama Pharma AB (publ)
- Enorama Pharma Q3 Operating Loss Widens To SEK 12.3 Mln
- Enorama Pharma CEO Daniel Schröder Resigns
- ERMA: Sharp revenue decline and deepening losses in H1 2025 amid US transition and PMTA focus
- ERMA: Losses deepened as Enorama Pharma restructures for US white snus growth and seeks new funding
Later from Enorama Pharma
- Enorama Pharma Postpones Its 2025 Year-End Report
- Enorama Pharma Enters Loan Agreement With DS Global
- Enorama Pharma AB (publ) resolves to postpone the planned extraordinary general meeting
- Enorama Pharma Postpones Publication Of 2025 Report Due To Control Balance Sheet
- Balance Sheet For Liquidation Purposes Shows Enorama Pharma Equity Is Less Than Half Of Registered Share Capital
Follow Enorama Pharma into a list and get an email when it puts out news.
Follow Enorama Pharma